EU Finds Rare Eye Risks in Ozempic and Other GLP-1 Diabetes Drugs
TL;DR Summary
The EU drugs regulator has identified a 'very rare' side effect of Ozempic, which can cause sight loss, highlighting the importance of monitoring adverse effects of medications.
- Ozempic has ‘very rare’ sight loss side effect, EU drugs regulator finds politico.eu
- Weight loss drugs linked to higher risk of eye damage in diabetic patients The Guardian
- Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says Reuters
- A kidney disease showdown, and eye risk linked to GLP-1s statnews.com
- Diabetes patients who use GLP-1s may have a higher risk of serious eye disease: study Fierce Pharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 1 min read
Condensed
79%
131 → 27 words
Want the full story? Read the original article
Read on politico.eu